

Built for the Biosimilar Race

High-performance cell culture media and optimization service built to accelerate your biosimilar development

With a high-performance CHO media portfolio, proven biosimilar media optimization experience, and reliable GMP manufacturing capabilities, OPM helps you move faster from process development to analytical similarity, without compromising performance or quality.



OPM-CHO Catalog Media

High-performance CHO Cell Culture Media for Biosimilars

The OPM-CHO portfolio comprises chemically defined, animal-origin-free, GMP-ready basal and feed media for high titer, high viable cell density, and extended culture viability in CHO bioprocesses.

- **96% average titer improvement** across evaluated applications
- **<5% batch-to-batch RSD** for consistent process performance
- **Dual-sourced critical raw materials** to strengthen supply-chain resilience
- **Two GMP manufacturing sites** supporting reliable supply and business continuity

Start with a stronger media platform and move faster toward a robust, scalable biosimilar process.

Project Showcase





Figure 1. (Top Left and Right) Four different combinations of OPM-CHO basal and feed media were used to produce an IgG4 biosimilar in a 16-day fed-batch run. Viable cell density (VCD), cell viability, and titer were compared against two global competitors. **(Left A, B, C, D)** Product quality characterization after 16-day fed-batch process with OPM 1-1 (blue) and the reference standard (gray).



Biosimilar Media Optimization Service

CQA Modulation to Drive Analytical Similarity

High titer alone does not make a biosimilar. When critical quality attributes (CQAs) fall outside the target range, our optimization service steps in. OPM applies targeted media optimization to modulate molecule-specific CQAs:

- Shift key CQAs toward the reference-product target profile
- Reduce iterative development cycles
- Establish analytical similarity earlier in development

From productivity to target CQAs, OPM helps you stay ahead in the biosimilar race.

Project Showcase





Figure 2. Media and process optimization modulated charge variants to levels comparable to the control.

Option 1: End-to-End Service (17 weeks)



Option 2: Flexible Service

